Sign in

    Brittany [ph]

    Senior Equity Research Analyst at Maxim Group

    Brittany Quatrochi is a Senior Equity Research Analyst at Maxim Group, specializing in healthcare and biotechnology sector research. She covers a range of innovative biotech companies including BioLineRx, Genetron Holdings, and Can-Fite BioPharma, and has established a strong track record with high accuracy ratings—maintaining a success rate near 70% and delivering above-average returns according to industry platforms like TipRanks. Brittany began her research career in the early 2010s with positions at LifeSci Capital and H.C. Wainwright & Co. before joining Maxim Group in 2018, where she has become recognized for her in-depth industry knowledge and actionable investment insights. She holds FINRA Series 7, 63, and 86/87 licenses and is known for her critical analysis and client-focused approach in the equity research field.

    Brittany [ph]'s questions to NATURAL GAS SERVICES GROUP (NGS) leadership

    Brittany [ph]'s questions to NATURAL GAS SERVICES GROUP (NGS) leadership • Q4 2024

    Question

    Brittany from Maxim Group asked if Natural Gas Services Group plans to expand its Tulsa facility following the closure of its Midland site and questioned the potential margin impact of outsourcing more manufacturing to third parties.

    Answer

    CEO Justin Jacobs stated there are no plans to expand the Tulsa facility, which handles smaller units for the rental fleet. He clarified that using third-party fabricators for larger units is a capital cost consideration and does not directly impact rental margins, which are driven by rental rates and ongoing operating expenses.

    Ask Fintool Equity Research AI